Wesper Journal

GLP-1 therapies, such as Zepbound (tirzepatide), address obstructive sleep apnea by aiding weight management, thereby reducing airway pressure and improving respiratory health. Wesper's wearable technology enhances treatment by providing continuous monitoring, allowing for timely adjustments to therapy plans. FDA’s Landmark...

This article explores the relationship between BMI, age, and gender in obstructive sleep apnea (OSA) severity and hypoxic burden. Analyzing two patient cohorts, the study finds that higher BMI is linked to increased apnea-hypopnea index (AHI) and hypoxic burden, though its effect plateaus in severe obesity. Age and male gender emerge as stronger predictors of OSA severity in obese individuals. The findings highlight the potential of GLP-1-induced weight loss to reduce OSA severity but emphasize the need for a multimodal approach, integrating weight management with traditional OSA treatments like CPAP for optimal patient outcomes.

Explanation of sleep and respiratory metrics reported by the Wesper PDF report Apnea/Hypopnea Index (AHI): The average number of apneas and hypopneas calculated per hour of sleep time. AHI may differ when the desaturation threshold is set at 3% or...